Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease.
Meilan K Han, Tyler A Barreto, Fernando J Martinez...
https://pubmed.ncbi.nlm.nih.gov/32071149/Actively Recruiting
Led by Applied Science & Performance Institute · Updated on 2026-09-17
60
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating whether the dietary supplements Quercefit4 and Ubiqsome2 can improve healthy aging markers, blood sugar control, and heart health in older adults. This randomized, double-blind, placebo-controlled study focuses on adults aged 50 to 75 who are sedentary and overweight or obese. The study also investigates the safety and potential side effects of these supplements. Participants are assigned to one of three groups Quercefit4 500 mg daily, given as 250 mg twice daily, Ubiqsome2 300 mg daily, given as 150 mg twice daily, or a placebo taken twice daily. The intervention lasts 12 weeks, with capsules taken morning and evening. Blood samples are collected at the beginning and end of the study at local labs. Remote assessments include grip strength testing using a mailed device, fatigue and quality of life surveys, and compliance monitoring. Throughout the study, participants complete fasting blood draws to measure inflammation, aging markers, glucose regulation, insulin sensitivity, lipid profiles, and cardiovascular risk factors. They also perform remote grip strength tests and complete electronic questionnaires. Adverse events and supplement usage are tracked regularly, with support from study staff to ensure adherence. The total participation duration is about 12 weeks.
CONDITIONS
The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health
T
Tony Zavala, BS
G
Gabe Wilson, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Applied Science & Performance Institute
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Quercefit® (Quercetin) supplement | Ubiqsome™ (Coenzyme Q10) supplement | Placebo control | Lifestyle change program (current standard) |
|---|---|---|---|---|
| What it is | A dietary quercetin supplement (Quercefit®) tested for effects on inflammation and metabolic aging markers | A dietary Coenzyme Q10 supplement (Ubiqsome™) evaluated as an active comparator | A placebo control with rice flour used to isolate supplement effects | Reduces risk of developing type 2 diabetes by about 58% overall and 71% in older adults |
| Role in trial | Experimental investigational supplement arm | Active comparator supplement arm | Placebo comparator arm | Current evidence‑based standard for managing prediabetes outside the trial |
| Primary use | Studied for reducing inflammation and improving metabolic aging markers | Tested for effects on similar inflammation and metabolic outcomes | Measure baseline change without active intervention | Implement lifestyle changes to delay or prevent type 2 diabetes onset |
| How it is given or performed | Oral dietary supplement Quercefit® | Oral dietary supplement Ubiqsome™ (CoQ10) | Oral placebo pills (rice flour) | Year‑long structured program with dietary advice, exercise goal of ≥150 min/week, and behavioral coaching |
| Evidence status | Effectiveness not yet established; under investigation in this trial | Effectiveness not yet established; being compared to placebo and quercetin | Serves as baseline comparator; efficacy inferred indirectly | CoQ10 may improve cardiovascular risk factors in prediabetes but requires more research |
| Important risks | Limited safety data in this population; dietary supplement risks unknown | Safety under investigation; previous studies suggest general tolerability but not established in this group | Inert placebo, minimal risk expected | Generally safe; based on behavior change, not drug therapy |
| Important limitations | Effect on clinical outcomes not yet known; trial limited to specific age and sedentary group | Efficacy unknown and may not outperform lifestyle intervention | Placebo arm does not reflect clinical care; no active intervention | Requires significant time and commitment; may not be feasible for all individuals |
| Patient impact | Not yet known | Unknown at this time | No expected benefit | Delays onset of type 2 diabetes, improving long‑term health outcomes |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility including age, health status, lifestyle, and prediabetes risk.
1 visit (in-person or remote)
Duration - 1 week
Participants complete fasting blood draws at a local lab and remote physical and survey assessments.
1 blood draw visit and remote assessments
Duration - 12 weeks
Participants take assigned capsules of Quercefit4, Ubiqsome2, or placebo twice daily for 12 weeks while logging compliance and side effects.
Regular check-ins remotely during this period
Duration - 1 week
Participants repeat fasting blood draws and remote grip strength and questionnaire assessments to measure changes.
1 blood draw visit and remote assessments
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Meilan K Han, Tyler A Barreto, Fernando J Martinez...
https://pubmed.ncbi.nlm.nih.gov/32071149/Alannah K A McKay, Trent Stellingwerff, Ella S Smith...
https://pubmed.ncbi.nlm.nih.gov/34965513/Francesco Di Pierro, Fazle Rabbani, Meherullah Tareen...
https://pubmed.ncbi.nlm.nih.gov/39990611/Zuyun Liu, Pei-Lun Kuo, Steve Horvath...
https://pubmed.ncbi.nlm.nih.gov/30596641/Antonella Riva, Massimo Ronchi, Giovanna Petrangolini...
https://pubmed.ncbi.nlm.nih.gov/30328058/Morgan E Levine, Ake T Lu, Austin Quach...
https://pubmed.ncbi.nlm.nih.gov/29676998/Applied Science & Performance Institute
Lead Sponsor